Latest COVID-19 guidelines come out against bamlanivimab, remdesivir
The NIH and the Infectious Diseases Society of America found insufficient data to support bamlanivimab, while the World Health Organization said the same about remdesivir. The FDA issued more emergency use authorizations, and research looked at racial and other disparities in COVID-19 outcomes.